EB 104
Alternative Names: EB-104Latest Information Update: 22 Nov 2022
At a glance
- Originator Unknown
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Diffuse large B cell lymphoma
Most Recent Events
- 03 Oct 2022 Early research in Diffuse large B cell lymphoma in USA (Parenteral)